On 2023-11-09, Avalo Therapeutics, Inc. (AVTX) announced earnings per share of $-26.19 for the fiscal quarter ending 2023-09-30, beating the average analyst estimate of $-261.90.
The next expected annoucement date for quarterly earnings is 2024-05-09, with an average estimated earnings per share of $-1.18 for the fiscal quarter ending 2024-03-31.
Note: Earnings figures are calculated as diluted earnings per share before non-recurring items and including employee stock options expenses.
| Announcement Date | Fiscal Quarter End | Estimated EPS | Actual EPS |
|---|---|---|---|
| 2023-11-09 | 2023-09-30 | $-261.90 | $-26.19 |
| 2023-08-03 | 2023-06-30 | $-214.29 | $-140.48 |
| 2023-05-04 | 2023-03-31 | $-230.95 | $-202.38 |
| 2023-03-29 | 2022-12-31 | $-123.81 | $-247.62 |
| 2022-11-07 | 2022-09-30 | $-245.24 | $80.95 |
| 2022-08-04 | 2022-06-30 | $-428.57 | $-328.57 |
| 2022-05-05 | 2022-03-31 | $-400.16 | $-571.66 |
| 2021-11-09 | 2021-09-30 | $-543.07 | $-485.91 |
| 2021-08-02 | 2021-06-30 | $-514.49 | $-514.49 |
| 2021-05-13 | 2021-03-31 | $-657.41 | $-914.65 |
| 2020-11-09 | 2020-09-30 | $-285.83 | $-457.33 |
| 2020-08-06 | 2020-06-30 | $-285.83 | $-428.74 |
| 2020-05-07 | 2020-03-31 | $-342.99 | $-114.33 |
| 2019-11-14 | 2019-09-30 | $-485.91 | $-200.08 |
| 2019-08-08 | 2019-06-30 | $-457.33 | $-371.58 |
| 2019-05-09 | 2019-03-31 | $-457.33 | $-371.58 |
| 2018-11-13 | 2018-09-30 | $-342.99 | $-743.15 |
| 2018-08-09 | 2018-06-30 | $-285.83 | $-285.83 |
| 2018-05-11 | 2018-03-31 | -- | $-200.08 |
| 2018-04-02 | 2017-12-31 | -- | $-314.41 |
| 2017-11-06 | 2017-09-30 | $-685.99 | $1486.31 |
| 2017-08-14 | 2017-06-30 | $-743.15 | $-400.16 |
| 2017-05-09 | 2017-03-31 | $-828.90 | $-543.07 |
| 2017-03-14 | 2016-12-31 | $-1857.89 | $-514.49 |
| 2016-11-08 | 2016-09-30 | $-1400.56 | $-2000.80 |
| 2016-08-15 | 2016-06-30 | $-1600.64 | $-1171.90 |
| 2016-05-16 | 2016-03-31 | $-1114.73 | $-1686.39 |
| 2016-03-23 | 2015-12-31 | -- | $-1514.89 |
| 2015-11-13 | 2015-09-30 | -- | $-428.74 |